Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 22 of 179 for:    ERYTHROMYCIN

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01379183
Recruitment Status : Completed
First Posted : June 23, 2011
Results First Posted : January 27, 2014
Last Update Posted : March 21, 2016
Sponsor:
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Jeff Fidler, Mayo Clinic

Brief Summary:
Magnetic Resonance Imaging (MRI) has proven to be a valuable imaging technique for suspected small bowel disease. This technique depends, in part, on adequate distension of the small bowel. This is accomplished by administering large volumes of a non-absorbable oral contrast material prior to the examination, which typically produces excellent distension of the distal small bowel and stomach, but poor distension of the proximal small bowel. Erythromycin is a common antibiotic that is known to promote stomach emptying and is used to treat diabetics with gastroparesis (poor stomach emptying.) The hypothesis of this study was that erythromycin will increase gastric emptying and hence improve small and large intestinal distention during MRI.

Condition or disease Intervention/treatment Phase
Healthy Drug: Erythromycin Drug: Placebo Procedure: Magnetic Resonance Imaging Other: Barium Sulfate Solution Phase 2 Phase 3

Detailed Description:
Gastric, small, and large intestinal volumes were assessed with MRI after ingestion of a low concentration of barium sulfate solution (1350 mL) and randomization to erythromycin 200 mg i.v.) or placebo in 40 healthy volunteers. Magnetic Resonance Images of the abdomen were acquired with a torso phased array coil and a 1.5 tesla magnet.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Supportive Care
Official Title: Magnetic Resonance (MR) Evaluation of the Effect of Erythromycin Upon Gastric and Small Bowel Motility
Study Start Date : June 2011
Actual Primary Completion Date : March 2012
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: MRI Scans

Arm Intervention/treatment
Active Comparator: Erythromycin
Erythromycin 200 mg i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
Drug: Erythromycin
200 mg suspension
Other Name: Erythromycin suspension

Procedure: Magnetic Resonance Imaging
An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
Other Names:
  • MRI
  • Magnetic Resonance Enterography

Other: Barium Sulfate Solution
Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
Other Name: VoLumen

Placebo Comparator: Placebo
Matching placebo i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
Drug: Placebo
200 mg suspension
Other Name: Water in 0.9% Sodium Chloride

Procedure: Magnetic Resonance Imaging
An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
Other Names:
  • MRI
  • Magnetic Resonance Enterography

Other: Barium Sulfate Solution
Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
Other Name: VoLumen




Primary Outcome Measures :
  1. Gastric Volume [ Time Frame: Approximately 60 minutes after beginning ingestion of fluid volume ]
    A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. MR images of the abdomen were acquired with a torso phased array coil and a 1.5 tesla magnet MRI. Gastric volumes were assessed with an axial 3D axial gradient echo sequence, which imaged the entire stomach in 13 seconds.


Secondary Outcome Measures :
  1. Jejunal Volume [ Time Frame: Approximately 60 minutes after beginning ingestion of fluid volume ]
    The jejunum is the section of the small intestine between the duodenum and the ileum. A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath.

  2. Ileal Volume [ Time Frame: Approximately 60 minutes after beginning ingestion of fluid volume ]
    The Ileal is the terminal portion of the small intestine extending from the jejunum to the cecum. A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath.

  3. Colonic Volume [ Time Frame: Approximately 60 minutes after beginning ingestion of fluid volume ]
    A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath.

  4. Small Intestine Volume [ Time Frame: Approximately 60 minutes after beginning ingestion of fluid volume ]
    A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath.

  5. Small Intestine and Colon Volume [ Time Frame: Approximately 60 minutes after beginning ingestion of fluid volume ]
    A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Normal healthy adult volunteers without known gastrointestinal disease
  • Aged 18-70 years
  • Able to provide written informed consent before participating in the study
  • Able to communicate adequately with the investigator and to comply with the requirements for the entire study.

Exclusion Criteria:

  • Known allergy to erythromycin;
  • Use of drugs that have known contraindication with erythromycin (concomitant therapy with astemizole, cisapride, pimozide, or terfenadine)
  • Corrected QT interval on EKG >460 msec
  • Certain medications (i.e., theophylline, digoxin, oral anti-coagulant, benzodiazepine, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors) will either be excluded from the study or, if medically safe, will be asked to discontinue the medication for 4 half-lives before beginning the study.
  • Use of medications that alter GI motility e.g., narcotics, medications with significant anticholinergic effects
  • Pregnant or breast-feeding females
  • Known claustrophobia
  • Known family history of sudden death or congenital QT prolongation
  • Presence of pacemaker, internal defibrillator, or other non-MR compatible device
  • Patients with known metal present within their abdomen

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01379183


Locations
Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Layout table for investigator information
Principal Investigator: Jeff Fidler, MD Mayo Clinic

Layout table for additonal information
Responsible Party: Jeff Fidler, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01379183     History of Changes
Other Study ID Numbers: 10-004869
P01DK068055 ( U.S. NIH Grant/Contract )
First Posted: June 23, 2011    Key Record Dates
Results First Posted: January 27, 2014
Last Update Posted: March 21, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Jeff Fidler, Mayo Clinic:
Healthy
Men
Women
No known gastrointestinal disease
Aged between 18-70 years
Additional relevant MeSH terms:
Layout table for MeSH terms
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Pharmaceutical Solutions
Anti-Bacterial Agents
Anti-Infective Agents
Gastrointestinal Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action